Concept Medical's products, based in Tampa, Florida;

"Concept Medical has always strived to find out of the box solutions to elevate health. With the attribute of being the first in class with the it’s natural indulgence of caregiving, it has dedicatedly worked in the field of Coronary Artery Disease and Peripheral Artery Disease. The Research and Development department combined with the unconventional yet inventive minds at Concept Medical is continuously infusing and inhibiting its energy towards etching new products in the field of Oncology.

They say, future is unpredictable, but Concept Medical daily sculpts the future for your good health.

A healthy mind and body is important to you and achieving that is imperative to us."


Abluminus DES+ is cobalt-chromium Sirolimus coated coronary drug eluting stent, the market first and only Drug Eluting Stent + Balloon. Abluminus DES+ features:

  • Both, stent and exposed parts of the balloon are covered with Sirolimus – upon inflation the thin and elastic film is created, which covers whole surface of stented vessel segment, offering short-term drug release from the balloon and longer term drug release from stent struts. This feature is especially beneficial in diabetic patients, with diffuse lesions.

  • The balloon is covered by Sirolimus 0.5 mm distally and proximally of the stent in order to address edge re-stenosis

  • Stent struts are covered on abluminal surface only so the endothelialisation process is better and faster, and systemic drug loss is smaller

  • Polymer used is proprietary combination of PLLA and PLGA – biocompatible and not provoking inflammatory response. The polymer is completely degraded after 180 day

  • Stent struts are 73 µm thick

  • Hybrid cell architecture – closed cells on proximal and distal end, to ensure higher radial force and open cells in the middle part to ensure more flexibility and good side branch access

Abluminus DES+ with 2200 patients in 1 year follow up shows excellent clinical data: MACE and TLR/TVR rate is 2.45% and 1.43% at 12 months. Diabetic patients sub-group analysis shows MACE of 3.12% and TLR/TVR is 1.82%.